期刊
PHARMACEUTICALS
卷 15, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/ph15111407
关键词
non-small cell lung cancer; pembrolizumab; neutrophil-to-lymphocyte ratio
资金
- National Science and Technology Council, Taiwan
- Center of Applied Nanomedicine, National Cheng Kung University [NSTC 111-2314-B-006-092-MY3]
- Featured Areas Research Center Program
This study compares the treatment efficacy of immune checkpoint inhibitors (ICIs) monotherapy with combination therapy in patients with advanced non-small cell lung cancer (NSCLC). The results show that combination therapy provides a better progression-free survival (PFS), especially in patients with low neutrophil-to-lymphocyte ratio (NLR).
The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naive advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing ICIs monotherapy with combination therapy either with chemotherapy or radiotherapy in programmed death-ligand 1 high expressors remain limited. This study aimed to retrospectively compare the treatment efficacy of the therapies by studying 47 patients with treatment-naive advanced NSCLC who received ICI monotherapy (n = 28) or combination therapy either with chemotherapy or radiotherapy (n = 19). Progression-free survival (PFS) and OS were estimated using the Kaplan-Meier method and compared using log-rank tests. It was observed that patients who received combination therapy had a better PFS than monotherapy, but no such significant benefit was observed in OS. The difference in PFS was higher in the subgroup of patients with low neutrophil-to-lymphocyte ratio (NLR) than in the high-NLR patient subgroup. This study suggests that pembrolizumab in combination with chemotherapy or radiotherapy could provide a significant benefit in PFS, especially in patients with treatment-naive advanced NSCLC with low NLR. Furthermore, our study also demonstrates the potential use of NLR as a biomarker for prediction of treatment outcomes in patients with advanced NSCLC receiving combination therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据